In re of:

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-31 (Canceled).

32. (Original) A method of using an MBL composition for preventing and/or reducing SARS in an individual, the method comprising the steps of:

a) determining serum levels of MBL in an individual,

b) estimating the probability of the occurrence of a significant clinical SARS in the individual, and optionally,

c) administering an MBL composition to the individual.

33-34 (Canceled).

35. (New) A method for preventing or treating Severe Acute Respiratory Syndrome, comprising administering an effective amount of a composition comprising at least one collectin and/or ficolin subunit, or at least one collectin and/or ficolin oligomer comprising the collectin and/or ficolin subunit, to an individual in need thereof.

36. (New) The method of claim 35, wherein the composition comprises at least one mannan-binding lectin (MBL) oligomer comprising the at least one mannan-binding lectin (MBL) subunit.

37. (New) The method of claim 36, wherein said oligomer is preferably selected from the group of oligomers consisting of tetramers, pentamers and/or hexamers.

38. (New) The method of claim 35, wherein the individual has a serum level of MBL in excess of 10 ng/ml serum.

39. (New) The method of claim 35, wherein the individual has a serum level of MBL in excess of 50 ng/ml serum.

40. (New) The method of claim 38, wherein the serum MBL level is the functional serum MBL level.

41. (New) The method of claim 39, wherein the serum MBL level is the functional serum MBL level.

42. (New) The method of claim 35, further comprising administering an antimicrobial medicament capable of attenuation and/or elimination a microbial species.

43. (New) The method of claim 42, further comprising administering an antibacterial medicament capable of bacterial attenuation and/or elimination.

44. (New) The method of claim 35, wherein the MBL subunit or the MBL oligomer is produced in a native host organism.

45. (New) The method of claim 44, wherein the native host organism is a human cell natively expressing the MBL subunit or the MBL oligomer.

46. (New) The method of claim 35, wherein the MBL subunit or MBL oligomer is produced by a host organism not natively expressing an MBL polypeptide.

47. (New) The method of claim 35, wherein the MBL subunit or the MBL oligomer is produced by a method comprising at least one step of recombinant DNA technology in vitro.

48. (New) The method of claim 46, wherein the production of the MBL subunit or the MBL oligomer is controlled by an expression control sequence not natively associated with MBL polypeptide expression.

49. (New) The method of claim 47, wherein the production of the MBL subunit or the MBL oligomer is controlled by an expression control sequence not natively associated with MBL polypeptide expression.

50. (New) The method of claim 44, wherein the MBL subunit or the MBL oligomer is isolated from the host organism.

51. (New) The method of claim 50, wherein the MBL subunit or the MBL oligomer is isolated by a method comprising at least one step involving affinity chromatography.

52. (New) The method of claim 50, wherein the affinity chromatography step is capable of isolating MBL tetramers, pentamers and/or hexamers from a composition further comprising additional MBL oligomers and/or MBL subunits.

53. (New) The method of claim 35, wherein the MBL subunit and/or the MBL oligomer is free from any impurities naturally associated with the MBL when produced in a native host organism.

54. (New) The method of claim 35, wherein the MBL subunit is a mammalian MBL subunit.

55. (New) The method of claim 54, wherein the mammalian MBL subunit is a human MBL subunit.

56. (New) The method of claim 35, wherein the medicament is administered to the individual prior to another treatment.

57. (New) The method of claim 35, wherein the administration is a booster of MBL serum levels in an individual having MBL serum levels above a predetermined minimum MBL serum level of 10 ng/ml.

58. (New) The method of claim 57, wherein the individual has MBL serum levels below a predetermined maximum MBL serum level of 500 ng/ml.

59. (New) The method of claim 35, wherein the individual has serum levels of MBL in excess of 75 ng/ml.

60. (New) The method of claim 35, wherein the individual has serum levels of MBL in excess of 100 ng/ml.

61. (New) The method of claim 35, wherein the individual has serum levels of MBL in excess of 150 ng/ml.

62. (New) The method of claim 35, wherein the individual has serum levels of MBL below 500 ng/ml.

63. (New) The method of claim 35, wherein the individual has serum levels of MBL below 400 ng/ml.

64. (New) The method of claim 35, wherein the individual has serum levels of MBL below 300 ng/ml.

65. (New) The method of claim 35, wherein serum or plasma levels of MBL in the individual are determined by quantitative analysis.

66. (New) The method of claim 65, wherein the analysis comprises at least one of ELISA, TRIFMA, RIA or nephelometry.